A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 199
- Registration Number
- NCT04791319
- Locations
- πΊπΈ
Park Avenue Dermatology, Orange Park, Florida, United States
πΊπΈClinical Partners, Johnston, Rhode Island, United States
π¨π¦Centre De Recherche Dermatologique Du Quebec Metropolitan, Quebec, Canada
A Study of JNJ-70075200 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-70075200Drug: Placebo
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04782661
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of JNJ-64304500 in Participants With Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Drug: JNJ-64304500Drug: Placebo
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04740970
- Locations
- π―π΅
The Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan
π―π΅Yamaguchi University Hospital, Ube, Japan
πΊπΈIcahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of JNJ-64300535 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: JNJ-64300535
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04736147
- Locations
- π§πͺ
SGS Belgium NV, Edegem, Belgium
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT04722146
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈWeill Cornell Medical College, New York, New York, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT04718805
- Locations
- π§πͺ
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64304500
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04712006
- Locations
- π¨π³
Peking University Third Hospital, Beijing, China
A Study of Guselkumab in Adult Participants With Celiac Disease
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04704843
- Locations
- πΊπΈ
West Michigan Clinical Research Center, Wyoming, Michigan, United States
πΊπΈHightower Clinical, Oklahoma City, Oklahoma, United States
πΊπΈClinical Trials Network, Lancaster, California, United States
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT04673357
- Locations
- πΊπΈ
Children's Center for Digestive Health Care, Atlanta, Georgia, United States
πΊπΈPenn State Hershey Children's Hospital, Hershey, Pennsylvania, United States
πΊπΈLevine Childrens at Atrium Health, Charlotte, North Carolina, United States
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
- Conditions
- X-Linked Retinitis Pigmentosa
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 97
- Registration Number
- NCT04671433
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
πΊπΈUniversity of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
π©π°Rigshospitalet Glostrup, Glostrup, Denmark